NCT00141973

Brief Summary

A systemic treatment with corticosteroids has been advocated for various bacterial infectious diseases. Since the production of CRP is down-regulated by corticosteroids, a smaller increase or a more rapid decrease of this acute phase protein will:

  1. 1.suggest attenuated systemic inflammation, but
  2. 2.does not necessarily reflect adequate therapy of the infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Nov 2004

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2004

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

September 1, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 2, 2005

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2005

Completed
Last Updated

May 14, 2008

Status Verified

May 1, 2008

First QC Date

September 1, 2005

Last Update Submit

May 13, 2008

Conditions

Sepsis

Keywords

ProcalcitoninSepsisCorticosteroids

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Acute exacerbation of chronic obstructive pulmonary disease (COPD) due to bacterial pneumonia

You may not qualify if:

  • Chronic systemic use of corticosteroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ospedale Regionale Bellinzona e Valli

Bellinzona, Canton Ticino, 6500, Switzerland

Location

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Andreas Perren, MD

    Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 1, 2005

First Posted

September 2, 2005

Study Start

November 1, 2004

Study Completion

December 1, 2005

Last Updated

May 14, 2008

Record last verified: 2008-05

Locations

CH(1)